- Home
- ELAB vs OGEN Comparison
ELAB vs OGEN Comparison
Compare ELAB & OGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | ELAB | OGEN |
|---|---|---|
| Founded | 2020 | 1996 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.8M | 3.6M |
| IPO Year | 2023 | N/A |
Fundamental Metrics
Financial Performance| Metric | ELAB | OGEN |
|---|---|---|
| Price | $3.46 | $0.83 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 706.4K | ★ 897.5K |
| Earning Date | 03-27-2026 | 03-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $285,948.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $3.03 | $0.74 |
| 52 Week High | $398.86 | $18.90 |
Technical Indicators
Market Signals| Indicator | ELAB | OGEN |
|---|---|---|
| Relative Strength Index (RSI) | 48.45 | 40.70 |
| Support Level | $3.03 | $0.88 |
| Resistance Level | $3.78 | $1.03 |
| Average True Range (ATR) | 1.08 | 0.06 |
| MACD | -0.00 | 0.00 |
| Stochastic Oscillator | 7.16 | 13.64 |
Price Performance
Historical ComparisonAbout ELAB Elevai Labs Inc.
PMGC Holdings Inc advancing in Medical Aesthetics and Biopharmaceutical Innovation. It specializes in Skin Aesthetics, Obesity, and Metabolic Health business.
About OGEN Oragenics Inc.
Oragenics Inc is engaged in the research and development of nasal delivery pharmaceutical medications in neurology and fighting infectious diseases. The company's product ONP-002 is a fully synthetic, non-naturally occurring neurosteroid, is lipophilic, and can cross the blood-brain barrier to rapidly reduce swelling, oxidative stress and inflammation while restoring proper blood flow through gene amplification. The Company operates in one reportable segment, which includes activities related to advancing the development of its concussion drug, ONP-002.